With DYNAMIKA™, biotech’s benefit from scalable system that supports rapid setup and user-friendly site workflows, ensuring imaging data is managed efficiently and in full compliance with regulatory standards.
Changing imaging vendor mid-program means new readers, new methods and a break in comparability that a regulator will notice. We stay with you from exploratory endpoint through to submission.
Continuity of method: The same platform, the same reading standards and the same charter logic from Phase I onward — so your Phase III data is comparable to what came before it.
Expertise, not just capacity: Radiologists qualified per study and per criteria, supported by imaging scientists who work on endpoint design rather than only on execution.
Built for scrutiny: A validated platform, 21 CFR Part 11 compliant, with a complete audit trail from upload to signed read.
Right-sized to the phase: A 20-patient Phase I doesn’t need Phase III infrastructure. Configuration scales to the protocol, not to a fixed package.
